Table 1.

Summarized ECG and HRV parameters for for Gαs^flx\flx cre+ (n = 8) and control (n = 8) and for Gαi2^flx\flx cre+ (n = 11) and control mice (n = 9) before and after tamoxifen

Animal ID	PR, ms	QRS, ms	QTC, ms	RR, ms	SD nn, ms	RMS SD, ms	TP, ms2	VLF, ms2	LF, ms2	HF, ms2	nLF, nu	nHF, nu
Gαs flx cre before tam	32.50 ± 1.50	9.84 ± 1.1	62.28 ± 2.08	96.9 ± 2.46	2.92 ± 0.65	2.08 ± 0.51	131 ± 5.58	60.23 ± 9.2	39.53 ± 7.6	30.21 ± 7.9	55.16 ± 7.9	42.7 ± 7.52
Gαs flx cre after tam	32.60 ± 1.22	9.92 ± 0.87	40.08 ± 2.07*	148.8 ± 4.05*	5.05 ± 1.00	7.14 ± 6.11	160 ± 82	85.12 ± 9.9	36.4 ± 8.9	37.35 ± 6.7	37.08 ± 3.82*	51.0 ± 4.60
Gαs control before tam	34.96 ± 0.82	11.35 ± 0.66	67.75 ± 0.55	95.57 ± 0.064	14.75 ± 3.50	15.20 ± 3.63	297 ± 84	185.35 ± 15.2	42.23 ± 8.1	57.26 ± 12.7	48.34 ± 7.34	51.63 ± 7.33
Gαs control after tam	38.81 ± 0.44	9.93 ± 0.27	67.05 ± 4.46	101.1 ± 0.95	12.51 ± 5.27	7.58 ± 0.62	200 ± 5.72	101.98 ± 5.9	48.6 ± 7.8	45.23 ± 7.2	49.27 ± 3.17	45.61 ± 4.44
Gαi2 flx cre before tam	33.12 ± 0.49	10.41 ± 0.63	69.84 ± 4.98	113.1 ± 8.4	23.8 ± 7.57	11.7 ± 2.66	215 ± 81.4	97.7 ± 8.2	56.1 ± 9.2	49.5 ± 5.8	47.5 ± 6.08	43.35 ± 3.09
Gαi2 flx cre after tam	34.06 ± 0.88	9.96 ± 0.37	69.21 ± 3.43	98.94 ± 7.8*	31.4 ± 6.64	13.6 ± 5.49	1302 ± 432	1201 ± 110	44.6 ± 7.8	31.2 ± 6.7	44.7 ± 5.97	30.21 ± 1.2*
Gαi2 control before tam	35.07 ± 0.31	9.52 ± 0.452	61.63 ± 3.78	119.9 ± 10.1	11.80 ± 4.50	8.24 ± 0.81	134 ± 15.8	65.6 ± 12.7	25.01 ± 5.2	21.76 ± 5.9	36.6 ± 6.15	32.7 ± 2.08
Gαi2 control after tam	36.33 ± 1.04	10.12 ± 0.35	62.36 ± 3.76	123.7 ± 1.7	5.778 ± 5.92	7.12 ± 0.97	248 ± 5.5	171.2 ± 10.2	27.1 ± 3.4	36.2 ± 7.2	35.4 ± 8.31	47.95 ± 3.55

^*P < 0.05, repeated-measures one-way ANOVA.

The comparisons are between mice before and after tamoxifen (tam) in the various groups over the various parameters. HRV, heart rate variability; RMS, root mean square; TP, total power; VLF, very low frequency; LF, low frequency; HF, high frequency; nLF, normalized low frequency; nHF, normalized high frequency; nu, normalized units.